A multicenter, double-blind, randomized parallel-group, study to demonstrate the effect of 24 weeks treatment with vildagliptin 100 mg qd as add-on to metformin 500 mg bid compared to metformin 1000 mg bid in patients with type 2 diabetes inadequately controlled on metformin 500 mg bid monotherapy.

Trial Profile

A multicenter, double-blind, randomized parallel-group, study to demonstrate the effect of 24 weeks treatment with vildagliptin 100 mg qd as add-on to metformin 500 mg bid compared to metformin 1000 mg bid in patients with type 2 diabetes inadequately controlled on metformin 500 mg bid monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Vildagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Mar 2008 Status changed from recruiting to in progress. Updated from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top